| William Andrew Morrison, DPT | |
|
22292 Us Highway 72, Athens, AL 35613-2604 | |
| (513) 247-4340 | |
| (513) 247-4360 |
| Full Name | William Andrew Morrison |
|---|---|
| Gender | Male |
| Speciality | Physical Therapist |
| Location | 22292 Us Highway 72, Athens, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629500475 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | PTH7903 (Alabama) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| William Andrew Morrison, DPT 2531 Rocky Ridge Rd, Suite 101, Vestavia, AL 35243-4415 Ph: (205) 978-7376 | William Andrew Morrison, DPT 22292 Us Highway 72, Athens, AL 35613-2604 Ph: (513) 247-4340 |
News Archive
Salix Pharmaceuticals, Ltd. today announced plans for the Hepatic Encephalopathy Living Program (H.E.L.P.). H.E.L.P. is a first-of-its-kind patient and health care provider support program for the management of hepatic encephalopathy (HE) and will launch on May 24, 2010. The program will provide patients with HE educational materials, co-pay assistance, treatment adherence support and a 24-hour toll-free hotline.
The Nanodermatology Society (NDS), a physician-led organization dedicated to the scientific and medical aspects of nanotechnology and dermatology, released its first position statement on the safety of nanotechnology in sunscreens.
American women have gotten fatter as it has become more socially acceptable to carry a few extra pounds, according to a new study.
Halozyme Therapeutics, Inc. today announced the commencement of a Phase 1 clinical study that will assess the effects of three approved prandial (mealtime) insulin analogs administered with its proprietary rHuPH20 (PH20) hyaluronidase enzyme compared to each of the analogs alone. This randomized, three-way cross-over design, euglycemic clamp study will compare the postprandial pharmacokinetics (PK) and glucodynamics (GD) of the insulin analogs.
Eli Lilly and Company's investigational compound ruboxistaurin may reduce vision loss from diabetes-induced eye disease, according to new analyses of previously reported data presented at the 2004 Joint Meeting of the American Academy of Ophthalmology and the European Society of Ophthalmology in New Orleans, La.
› Verified 3 days ago
Helen J Block, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 209 Fitness Way Ste D, Athens, AL 35611 Phone: 256-233-9148 Fax: 256-233-9164 | |
Benchmark Pt - Athens Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 936 Us Highway 72 E Ste 170, Athens, AL 35611 Phone: 256-230-1252 Fax: 256-230-1256 | |
Joseph J Kribs, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 209 Fitness Way Ste D, Athens, AL 35611 Phone: 256-233-9148 Fax: 256-233-9164 | |
Mrs. Farrah Renee Haley, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 209 Fitness Way, Suite D, Athens, AL 35611 Phone: 256-233-9148 Fax: 256-233-9164 | |
P4 Physical Therapy Limited Partnership Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 15641 E Limestone Rd, Athens, AL 35613 Phone: 256-937-1360 | |
Mrs. Abreia R Thomas, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1260 Us Highway 72 E, Suite A, Athens, AL 35611 Phone: 256-233-4486 Fax: 256-230-6908 | |
Sarah Lancaster, PT, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 22454 Us Highway 72 # 210, Athens, AL 35613 Phone: 256-233-4486 |